Swiss National Bank
BTAI icon

Swiss National Bank’s BioXcel Therapeutics BTAI Stock Holding History

Swiss National Bank’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,763
Closed -$112K – 2552
2023
Q3 		$112K Hold
2,763
– – ﹤0.01% 2608
2023
Q2 		$294K Buy
2,763
+119
+5% +$39.6K ﹤0.01% 2593
2023
Q1 		$789K Sell
2,644
-250
-9% -$107K ﹤0.01% 2374
2022
Q4 		$995K Hold
2,894
– – ﹤0.01% 2347
2022
Q3 		$547K Hold
2,894
– – ﹤0.01% 2537
2022
Q2 		$611K Hold
2,894
– – ﹤0.01% 2562
2022
Q1 		$968K Buy
2,894
+244
+9% +$70.7K ﹤0.01% 2419
2021
Q4 		$862K Hold
2,650
– – ﹤0.01% 2528
2021
Q3 		$1.29M Hold
2,650
– – ﹤0.01% 2313
2021
Q2 		$1.23M Buy
2,650
+562
+27% +$306K ﹤0.01% 2382
2021
Q1 		$1.44M Buy
2,088
+194
+10% +$156K ﹤0.01% 2189
2020
Q4 		$1.4M Sell
1,894
-206
-10% -$160K ﹤0.01% 2125
2020
Q3 		$1.46M Buy
2,100
+687
+49% +$516K ﹤0.01% 1874
2020
Q2 		$1.2M Buy
+1,413
New +$921K ﹤0.01% 2003

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swiss National Bank's BTAI Position: Q4 2023 in Review

Swiss National Bank sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 2,763 shares — an estimated $112K sold.

Swiss National Bank first reported a position in BTAI in Q2 2020 and held it in 14 quarters. The position peaked at $1.46M in Q3 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Swiss National Bank reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Swiss National Bank sold 2,763 BioXcel Therapeutics shares in Q4 2023, an estimated $112K.
  • Swiss National Bank first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 14 quarters.
  • Swiss National Bank's BioXcel Therapeutics position peaked at $1.46M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.